AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEXT SCIENCE LTD

0.068

-0.001-1.45%

Volume:261.24K

Turnover:17.66K

Market Cap:19.87M

PE:-1.22

High:0.069

Open:0.069

Low:0.065

Close:0.069

Loading ...

Overview Company News Filings

Next Science Says Complaint Filed by Ex-Employee Dismissed by Court; Shares Up 4%

MT Newswires Live

BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court

Next Science - Derivative Complaint Filed by Individual Been Dismissed by Court for Lack of Standing

THOMSON REUTERS

BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3M

Next Science Ltd - 1Q FY25 Product Sales of US$5.3M

THOMSON REUTERS

Would Next Science (ASX:NXS) Be Better Off With Less Debt?

Simply Wall St.

Next Science Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

BRIEF-Next Science Posts Loss For The Year Of $10.6 Mln

Next Science Ltd - Loss for the Year $10.6 Mln

THOMSON REUTERS

Next Science Receives FDA Warning Letter Over Marketing Claims, Quality Issues; Shares Fall 8%

MT Newswires Live

BRIEF-Next Science Receives FDA Warning Letter

Next Science sinks after FDA warning letter implies product could have caused injury

The Market Herald

Next Science Ltd - Next Science Receives FDA Warning Letter

THOMSON REUTERS

Next Science - Undertaken Corrective Actions to Address Matters Raised by FDA, Including Revising Product Descriptions on Co's Website

THOMSON REUTERS

BRIEF-Next Science Posts FY24 Revenue Of $22.8M

Next Science Ltd - FY24 Revenue of US$22.8M

THOMSON REUTERS

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Simply Wall St.

Bathurst Resources Leads These 3 ASX Penny Stocks To Consider

Simply Wall St.

Next Science Says Former Employee Files Derivative Complaint in US Court

MT Newswires Live

BUZZ-Australia's Next Science plunges on litigation filed by ex-employee

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NXS.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NXS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXS.AU\",,,,,undefined,":{"symbol":"NXS.AU","market":"AU","secType":"STK","nameCN":"NEXT SCIENCE LTD","latestPrice":0.068,"timestamp":1749190320000,"preClose":0.069,"halted":0,"volume":261242,"delay":0,"nameEN":"NEXT SCIENCE LTD","floatShares":139470663,"shares":292160234,"eps":-0.05561121937468594,"marketStatus":"Closed King Birthday Day","change":-0.001,"latestTime":"06-06 16:12:00 AEST","open":0.069,"high":0.069,"low":0.065,"amount":17660,"amplitude":0.057971,"askPrice":0.068,"askSize":58490,"bidPrice":0.067,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.05561121937468594,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.069,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":1.5034714722475437,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXS.AU\",,,,,undefined,":{"symbol":"NXS.AU","floatShares":139470663,"roa":"-47.12%","roe":"-130.18%","lyrEps":-0.055561,"volumeRatio":1.5034714722475437,"shares":292160234,"dividePrice":0,"high":0.069,"amplitude":0.057971,"preClose":0.069,"low":0.065,"week52Low":0.065,"pbRate":"3.77","psRate":"0.57","week52High":0.305,"institutionHeld":0,"latestPrice":0.068,"committee":-0.078256,"eps":-0.05561121937468594,"divideRate":0,"volume":261242,"delay":0,"ttmEps":-0.05561121937468594,"open":0.069,"prevYearClose":0.115,"prevWeekClose":0.068,"prevMonthClose":0.069,"prevQuarterClose":0.11,"fiveDayClose":0.069,"twentyDayClose":0.099,"sixtyDayClose":0.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXS.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533373229","title":"Next Science Says Complaint Filed by Ex-Employee Dismissed by Court; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533373229","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533373229?lang=en_us&edition=fundamental","pubTime":"2025-05-05 11:23","pubTimestamp":1746415391,"startTime":"0","endTime":"0","summary":"Next Science  said the derivative complaint filed by former employee Michael Morello in Florida's Duval County Court has been dismissed for lack of standing, according to a Monday filing with the Australian bourse.The complaint alleges that the company's Xbio technology has not been approved by the US Food and Drug Administration for biofilm eradication and that the company failed to address safety concerns regarding its Xperience surgical solution in breast implant procedures, the company said in a Jan. 8 filing.The litigation initiated by the company against Morello and other former employees for breach of post-employment restraints is underway.Next Science's shares rose more than 4% in midday trade Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2533322606","title":"BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2533322606","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533322606?lang=en_us&edition=fundamental","pubTime":"2025-05-05 09:05","pubTimestamp":1746407130,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Says Derivative Complaint Filed By Individual Been Dismissed By Court May 5 (Reuters) - Next Science Ltd NXS.AX:DERIVATIVE COMPLAINT FILED BY INDIVIDUAL BEEN DISMISSED BY COURT FOR LACK OF STANDINGFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RA2AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2533932500","title":"Next Science - Derivative Complaint Filed by Individual Been Dismissed by Court for Lack of Standing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533932500?lang=en_us&edition=fundamental","pubTime":"2025-05-05 06:44","pubTimestamp":1746398695,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250504:nFWN3RA2AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2529696884","title":"BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2529696884","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529696884?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:03","pubTimestamp":1745453026,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Says 1Q FY25 Product Sales Of $5.3MApril 24 (Reuters) - Next Science NXS.AX:1Q FY25 PRODUCT SALES OF US$5.3MFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R11AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU"],"gpt_icon":0},{"id":"2529662678","title":"Next Science Ltd - 1Q FY25 Product Sales of US$5.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2529662678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529662678?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:22","pubTimestamp":1745446961,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R11AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2520535614","title":"Would Next Science (ASX:NXS) Be Better Off With Less Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520535614","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520535614?lang=en_us&edition=fundamental","pubTime":"2025-03-18 07:35","pubTimestamp":1742254523,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-nxs/next-science-shares/news/would-next-science-asxnxs-be-better-off-with-less-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NXS.AU","EBIT","BK7126"],"gpt_icon":0},{"id":"2516521390","title":"Next Science Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2516521390","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516521390?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:10","pubTimestamp":1740964201,"startTime":"0","endTime":"0","summary":"ASX:NXS Earnings and Revenue Growth March 3rd 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 18%. Earnings per share  exceeded analyst estimates by 5.8%.Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.The company's shares are down 8.7% from a week ago.You still need to take note of risks, for example - Next Science has   4 warning signs    we think you should know about.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/next-science-full-2024-earnings-011001043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NXS.AU"],"gpt_icon":0},{"id":"2514656363","title":"BRIEF-Next Science Posts Loss For The Year Of $10.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514656363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514656363?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:06","pubTimestamp":1740704776,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Posts Loss For The Year Of $10.6 MlnFeb 28 (Reuters) - Next Science Ltd NXS.AX:LOSS FOR THE YEAR $10.6 MILLIONFY REVENUES FROM ORDINARY ACTIVITIES UP 3% TO $ 22.8 MILLIONFurther company coverage: NXS.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI1UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514353945","title":"Next Science Ltd - Loss for the Year $10.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353945?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:36","pubTimestamp":1740692186,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514433058","title":"Next Science Receives FDA Warning Letter Over Marketing Claims, Quality Issues; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514433058","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514433058?lang=en_us&edition=fundamental","pubTime":"2025-02-25 14:54","pubTimestamp":1740466497,"startTime":"0","endTime":"0","summary":"Next Science  has received a warning letter from the US Food and Drug Administration  following an inspection of its Jacksonville, Florida facility in August and September 2024, according to a Tuesday filing with the Australian bourse.In its letter, the FDA determined that the company's Xperience, Blastx, and Surgx products did not have premarket approval related to certain marketing and labeling claims, the filing said.The FDA also identified potential quality system violations during the inspection of the facility.The company has implemented corrective actions and is working with the FDA to resolve the matters, while a follow-up inspection will be required to assess progress, the filing added.Shares of the company fell past 8% at market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2514703089","title":"BRIEF-Next Science Receives FDA Warning Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514703089","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514703089?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:29","pubTimestamp":1740446987,"startTime":"0","endTime":"0","summary":"BRIEF-Next Science Receives FDA Warning LetterFeb 25  - Next Science Ltd NXS.AX:NEXT SCIENCE RECEIVES FDA WARNING LETTERWARNING LETTER RELATES TO FDA'S INSPECTION OF CO'S JACKSONVILLE, FLORIDA FACILITY DURING AUG & SEPT 2024UNDERTAKEN CORRECTIVE ACTIONS TO ADDRESS MATTERS RAISED BY FDA, INCLUDING REVISING PRODUCT DESCRIPTIONS ON CO'S WEBSITEFurther company coverage: NXS.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2514908483","title":"Next Science sinks after FDA warning letter implies product could have caused injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2514908483","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514908483?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:56","pubTimestamp":1740444960,"startTime":"0","endTime":"0","summary":"Next Science  shares fell -13% on Tuesday morning trades, to 10cps, after the company revealed it’s received a warning letter from the FDA.The news isn’t what investors really want to hear – evidenced by the sell-off on Tuesday. Then again, getting a warning letter from the FDA is quite clearly undesirable in itself.The company, developing its XBIO product suite – in a word, bacterial biofilms – basically got told to clean up its facility after a visit by the FDA in August and September of last year.But there was one more worrying point buried in NXS’s Tuesday announcement.“During the inspection, the FDA found that Next Science had failed to timely submit reports to the FDA regarding information that suggested a device marketed by the Company may have contributed to serious injury,” the company wrote.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certif","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/next-science-sinks-after-fda-warning-letter-implies-product-could-have-caused-injury-2025-02-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514704226","title":"Next Science Ltd - Next Science Receives FDA Warning Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704226?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:27","pubTimestamp":1740436037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2514047267","title":"Next Science - Undertaken Corrective Actions to Address Matters Raised by FDA, Including Revising Product Descriptions on Co's Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2514047267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514047267?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:27","pubTimestamp":1740436037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2505508258","title":"BRIEF-Next Science Posts FY24 Revenue Of $22.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2505508258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505508258?lang=en_us&edition=fundamental","pubTime":"2025-01-23 09:26","pubTimestamp":1737595576,"startTime":"0","endTime":"0","summary":"Jan 23 (Reuters) - Next Science Ltd   :   * FY24 REVENUE OF US$22.8M Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXS.AU"],"gpt_icon":0},{"id":"2505706075","title":"Next Science Ltd - FY24 Revenue of US$22.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706075?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:21","pubTimestamp":1737580878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI14S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXS.AU","BK7126"],"gpt_icon":0},{"id":"2505085565","title":"Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely","url":"https://stock-news.laohu8.com/highlight/detail?id=2505085565","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505085565?lang=en_us&edition=fundamental","pubTime":"2025-01-23 04:26","pubTimestamp":1737577606,"startTime":"0","endTime":"0","summary":"Next Science Limited ( ASX:NXS ) shareholders would be excited to see that the share price has had a great month...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-nxs/next-science-shares/news/even-with-a-26-surge-cautious-investors-are-not-rewarding-ne-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NXS.AU","BK7126","ISBC","BK4211"],"gpt_icon":0},{"id":"2503531399","title":"Bathurst Resources Leads These 3 ASX Penny Stocks To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2503531399","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503531399?lang=en_us&edition=fundamental","pubTime":"2025-01-16 15:11","pubTimestamp":1737011462,"startTime":"0","endTime":"0","summary":"The Australian market has shown resilience, with the ASX200 closing up 1.38% at 8,327 points amid a backdrop of steady unemployment figures and strong sector performances in Financials and Real Estate. As investors navigate these conditions, identifying stocks with solid financial foundations becomes crucial. Penny stocks, despite their outdated moniker, can still offer surprising value when backed by robust fundamentals; this article explores three such opportunities that might appeal to those seeking under-the-radar investments with potential for growth.Click here to see the full list of 1,027 stocks from our ASX Penny Stocks screener.Overview: Bathurst Resources Limited focuses on the exploration, development, and production of coal in New Zealand, with a market capitalization of A$141.61 million.Overview: Iltani Resources Limited is involved in the exploration and development of metal projects in Australia, with a market cap of A$10.88 million.Operations: Iltani Resources Limited h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bathurst-resources-leads-3-asx-071102866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7070","XAO.AU","SKS.AU","EVO.AU","ILT.AU","XJO.AU","SHA.AU","BRI.AU","VLS.AU","BK7088","HLO.AU","BK7095","BK7126","ANG.AU","BK7129","XKO.AU","BK7055","BK7133","BK7164","MXI.AU","LBL.AU","NXS.AU","BRL.AU","BK7132","SRV.AU","BK7096","BK7023","BK7077","BK7114"],"gpt_icon":0},{"id":"2501713926","title":"Next Science Says Former Employee Files Derivative Complaint in US Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2501713926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501713926?lang=en_us&edition=fundamental","pubTime":"2025-01-08 14:49","pubTimestamp":1736318998,"startTime":"0","endTime":"0","summary":"Next Science  said that former employee Michael Morello has filed a derivative complaint in Florida's Duval County Court, alleging breaches of fiduciary duties and mismanagement by several employees, according to a Wednesday filing with the Australian bourse.Morello, who was Vice President of Wound Care Sales until December 2023, is also involved in a separate legal case initiated by the company in May 2024, alleging that he and other former employees breached post-employment restraints, the filing said.Meanwhile, Morello's complaint claims Next Science's XBIO technology is not FDA-approved for biofilm eradication, and safety concerns about its Xperience surgical solution in breast implant procedures were not addressed, the filing added.The company asserts that its products are FDA-approved, safe, and effective.Next Science is conducting an independent investigation and will continue pursuing its non-compete action against Morello and former employees.Shares of the company rose past 4%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","NXS.AU"],"gpt_icon":0},{"id":"2501102761","title":"BUZZ-Australia's Next Science plunges on litigation filed by ex-employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2501102761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501102761?lang=en_us&edition=fundamental","pubTime":"2025-01-08 10:01","pubTimestamp":1736301698,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Next Science plunges on litigation filed by ex-employee** Next Science NXS.AX slumps as much as 13% to record low of A$0.1; set for weakest trading session since October 2024** Medical tech firm says a former employee filed litigation in the U.S., alleging breaches of fiduciary duties and mismanagement against several employees** Litigation makes several claims - that certain tech has not been approved by U.S. FDA and that co did not take sufficient measures to address safety concerns about the use of its surgical solution in breast implant procedures** Co says its products are safe, effective and FDA-approved** Stock fell 66.2% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nL4N3O403L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","NXS.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXS.AU\",params:#limit:5,,,undefined,":[{"date":"2025-04-24","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745452800000,"name":null,"time":"","dateTimestamp":1745416800000,"actualEps":null},{"date":"2025-02-27","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740610800000,"name":null,"time":"","dateTimestamp":1740574800000,"actualEps":null},{"date":"2025-01-22","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1737500400000,"name":null,"time":"","dateTimestamp":1737464400000,"actualEps":null},{"date":"2024-10-21","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1729465200000,"name":null,"time":"","dateTimestamp":1729429200000,"actualEps":null},{"date":"2024-08-30","symbol":"NXS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724976000000,"name":null,"time":"","dateTimestamp":1724940000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXS.AU\",market:\"AU\",,,undefined,":[]}}